Últimas noticias sobre Rezolve AI (NASDAQ:RZLV) Bolsa

Rezolve AI

Rezolve AI Ltd provides a mobile commerce and engagement platform, underpinned by machine learning, that enables retailers, brands and manufacturers to engage with consumers in a broad range of locations and settings via their mobile devices and personal computers. its platform allows for mobile engagement with merchants using its software to extend their business to consumers' mobile devices and computers in different ways.

Rezolve AI Ltd

Goldman Sachs said in a research note released on Tuesday that it expects continued progress in the autonomous vehicles space, including robotaxis, <a href="https://www.benzinga.com/24/12/42455654/wedbush-securities-sees-tesla-touching-2-trillion-market-cap-by-2025-end-apple-microsoft-nvidia-to-join-4-trillion-market-cap-club-next-year-says-analyst">in 2025.&nbsp;</a>
Expert Ideas: Goldman Sachs analysts predict that vehicles with situationally "eyes-off," or Level 3, AV capabilities will reach approximately 10% of new vehicle sales in 2030. The analysts expect sales of fully autonomous vehicles, Levels 4 and 5, to be relatively low in the near to medium term, but to reach more than one million in 2028 and above two million in 2030.
The firm sees fully autonomous vehicles reaching a mid-teens percentage of global vehicle sales in 2040, including personal ownership of Level 4 vehicles. &nbsp;
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42440681/markets-have-the-green-light-to-rally-after-novembers-yawner-inflation-report-experts-say">&#8216;Markets Have The Green Light To Rally&#8217; After November&#8217;s &#8216;Yawner&#8217; Inflation Report, Experts Say</a> &nbsp;
TSLA: Goldman Sachs highlighted Tesla in the areas of power and platforms, but sees the EV-leader facing headwinds in its core auto business in the near to medium term. The firm pointed to slower global EV demand and pricing pressures as the causes.&nbsp;
Tesla is targeting a 2025 launch of its robotaxi service in Texas and/or California using its Model 3/Y vehicles. The company is also planning to begin production of its Cybercab robotaxi in 2026. Goldman Sachs pointed to increased federal regulatory clarity, especially for consumer vehicles, as being helpful to Tesla as it attempts to scale its Level 4 AVs.&nbsp;
Goldman Sachs maintained a Neutral rating on Tesla stock and raised its price target from $250 to $345.
RIVN: Goldman Sachs noted that Rivian recently deployed its Autonomy+ platform, currently a Level 2 AV driver assist and autonomy feature. Autonomy+ rolled out as a free trial and the firm expects Rivian to monetize the platform in the future, adding another revenue stream for the company.&nbsp;
Goldman Sachs maintained a Neutral rating on Rivian stock and raised its price target from $12 to $13.&nbsp;
TSLA, RIVN Price Action: According to Benzinga Pro, Tesla shares are down 0.42% at $423.00 and Rivian shares are up 1.15% at $13.92 at the time of publication Thursday at midday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42370672/sofi-makes-spacex-accessible-for-retail-investors">SoFi Unlocks SpaceX Exposure For Retail Investors: Here&#8217;s How</a></li>
</ul>
Image: Shutterstock&nbsp;

Analyst Color

News

Analyst Ratings

Movers

Tech

RIVN

TSLA

Rivian, Tesla Will Drive Autonomous Vehicle Progress In 2025: Goldman Sachs

On Thursday, Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) outlined its 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42456151/centene-corporation-announces-2025-guidance" rel="noreferrer noopener">financial guidance</a>.
For fiscal year 2025, the health insurance plan provider expects total revenues of&nbsp;$166.5 billion&nbsp;to&nbsp;$169.5 billion, compared to a consensus of $166.58 billion.
The guidance includes premium and service revenues of&nbsp;$154.0 billion&nbsp;to&nbsp;$156.0 billion. The company expects GAAP EPS of greater than&nbsp;$6.19, with adjusted EPS of greater than&nbsp;$7.25 compared to the consensus of $6.97.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The company expects a Health benefits ratio (HBR) of 88.4% to 89.0%.
The insurer forecasts a 2025 selling, general, and administrative (SG&amp;A) expense ratio of 8.1% to 8.7%, with an adjusted SG&amp;A expense ratio of 8.1% to 8.7%.
The company reaffirms its 2024 premium and service revenues guidance if&nbsp;$143.5 billion&nbsp;to&nbsp;$144.5&nbsp;billion, HBR guidance if 88.3% to 88.5%, and adjusted diluted EPS guidance <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41542651/centene-says-it-is-positioned-to-capture-long-term-growth-in-government-sponsored-healthcare-lifts-" rel="noreferrer noopener">of greater than&nbsp;$6.80</a>.
&#8220;Centene is a mission driven organization, dedicated to delivering high quality outcomes for more than 28 million members, many of whom are among the nation&#8217;s most medically complex and historically underserved populations. Over the last three years we improved our core operations and invested in the experience of our customers and providers, all while delivering on our financial commitments,&#8221; said Chief Executive Officer of Centene,&nbsp;Sarah London.
Full-year 2024 earnings will be reported on February&nbsp;4, 2025.
Price Action: CNC stock is up 1.92% at $57.99 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42462096/keros-therapeutics-pauses-two-treatment-arms-in-mid-stage-hypertension-trial-stock-plummets" target="_blank" rel="noreferrer noopener">Keros Therapeutics Loses 75% Value In A Single Session &#8211; Here&#8217;s Why</a></li>
</ul>

Earnings

Large Cap

Guidance

Health Care

Trading Ideas

General

Why Is Insurance Firm Centene Stock Trading Higher On Thursday?

LBGJ

Li Bang International Shares Halted On Circuit Breaker To The Upside, Stock Now Down -19.7%

Li Bang International Shares Resume Trade

Goldman Sachs analyst Neil Mehta rated Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) Neutral <a target="_blank" href="https://www.benzinga.com/quote/XOM/analyst-ratings" rel="noreferrer noopener">and a price target of $125</a>.
Yesterday, the company unveiled its Corporate Plan to 2030, targeting an additional $20 billion in earnings and $30 billion in <a target="_blank" href="https://www.benzinga.com/24/12/42444546/2030-roadmap-exxonmobil-to-achieve-54m-barrelsday-production-targets-20-billion-earnings-boost" rel="noreferrer noopener">cash flow over the next six years</a>.
The 2030 goals include increasing Pioneer acquisition synergies by 50% to over $3 billion annually, growing <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">new business earnings to $3 billion</a>.
ExxonMobil is targeting up to $30 billion in lower-emissions investments and will allocate $27 billion – $29 billion in capex for 2025, with annual investments of $28 billion – $33 billion from 2026 to 2030, while reducing the reinvestment rate to 40%.
The analyst says that Exxon highlighted its differentiated Permian position post-Pioneer acquisition, leveraging non-sand proppants for better well performance.
Mehta notes that over the next 12 months, the company plans to deploy the technology in over 200 wells, though supply chain constraints remain a key focus for managing the deployment cadence.
However, Exxon was more cautious than expected regarding its 2030 volume outlook for Guyana, with forecasts set at 1.3 million bpd, compared to Goldman Sachs&#8217; estimate of 1.5 million bpd, adds the analyst.
Mehta says that the company emphasized its ongoing focus on using 4D seismic technology and expanding high-performance computing capacity to enhance resource recovery and maximize value capture. 
Additionally, the analyst notes that ExxonMobil is continuing to collaborate closely with the Guyanese government on gas development projects.
Going forward, the analyst says that it will closely monitor management&#8217;s updates on the execution of various LNG projects, particularly Golden Pass, due to previous challenges with execution and timing.
The analyst estimates EPS of $7.91 for 2024, $8.35 for 2025 and $9.71 for 2026.
Investors can gain exposure to XOM via&nbsp;EA Series Trust Strive U.S. Energy ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRLL#NYSE">DRLL</a>) and&nbsp;Vanguard Energy Index Fund ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDE#NYSE">VDE</a>).
Price Action: XOM shares are down 0.39% at $111.48 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/content/42460201/why-betting-on-oil-over-gold-could-pay-off-big-in-2025" target="_blank" rel="noreferrer noopener">Why Betting on Oil Over Gold Could Pay Off Big in 2025</a></li>
</ul>
Photo: Del Henderson Jr. via Shutterstock.

Equities

Price Target

Reiteration

DRLL

Exxon Has A Differentiated Permian Position Post-Pioneer Deal: Goldman Sachs Analyst

Li Bang International Shares Halted On Circuit Breaker To The Upside, Stock Now Down -26.9%

Hyperliquid (CRYPTO: HYPE), a rising decentralized exchange and Layer-1 blockchain, continues its strong rally, which has seen the token price increase six-fold from $3 to over $18 since its much-anticipated launch <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42242292/trader-scores-over-800000-from-crypto-airdrop-thank-you-for-the-life-changing-wealth-generation-event">two weeks ago.</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Hyperliquid (CRYPTO: HYPE)</td>
<td>&nbsp;$18.20</td>
<td>$4.9 billion</td>
<td>+16%&nbsp;</td>
<td>+43.4%&nbsp;</td>
</tr>
<tr>
<td>Sui (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SUI</a>)</td>
<td>&nbsp;$4.63</td>
<td>$13.5 billion</td>
<td>+9.9%&nbsp;</td>
<td>&nbsp;+10.3%</td>
</tr>
<tr>
<td>BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>)</td>
<td>&nbsp;$719.9</td>
<td>$103.7 billion</td>
<td>+3.3%&nbsp;</td>
<td>-1.7%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Daniel <a href="https://x.com/danielgothits/status/1862541671311056908">described</a> Hyperliquid as the "coolest new product in years, saying it is "basically Binance, except fully on-chain with no KYC, usernames or logins."
Other traders echoed the positive sentiment, with zkTuring <a href="https://x.com/zkTuring/status/1866869827992011238?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1866869827992011238%7Ctwgr%5E058f1ea80d94d4c99e854e659c860ea6bd0438b0%7Ctwcon%5Es1_c10&amp;ref_url=https%3A%2F%2Feditorial.benzinga.com%2Fwp-admin%2Fpost.php%3Faction%3Deditpost%3D689853">saying</a> &#8220;imagine Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Binance (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>) and FTX (without the fraud) had a baby.&#8221;
Hoeem, another crypto analyst, likened HYPE's potential to the rally of Celestia (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TIA</a>) after its launch, noting the absence of <a href="https://x.com/crypthoem/status/1867206894013599864">venture</a> capital involvement. He marked $20 as a critical psychological level, predicting a significant pump if surpassed.
Ryan Watkins, co-founder of Syncracy Capital, expressed <a href="https://x.com/RyanWatkins_/status/1866875152434168037">confidence</a> in Hyperliquid surpassing SUI, stating that HYPE is the only emerging Layer-1 trading at one-third to one-fifth the valuation of its closest competitors. 
He added that Hyperliquid's aspirational comparison is BNB.
Statistics: Technical analyst SatsHunter <a href="https://x.com/SatsHunter_/status/1866898924822233125">highlighted</a> Hyperliquid's impressive fundamentals, including:
<ul>
<li>$2.25 billion in total value locked (TVL).</li>
<li>58% dominance in on-chain perpetuals.</li>
<li>$70 billion in monthly perpetual trading volume.</li>
</ul>
He emphasized that 38.88% of HYPE's token supply is still designated for community distribution, signaling further growth potential.
Trader blue4k <a href="https://x.com/bluegwei/status/1867205261339095498">echoed</a> the bullish sentiment, pointing to Hyperliquid's exclusively native components. 
The scheduled launch of the HyperEVM in early 2025 is also expected to be a <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42319671/ethereum-killer-hyperliquid-explodes-for-274-7-day-gain-could-create-more-millionaires-than-microsoft-at-this-rate-trader-says">significant growth catalyst</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42319671/ethereum-killer-hyperliquid-explodes-for-274-7-day-gain-could-create-more-millionaires-than-microsoft-at-this-rate-trader-says">&#8216;Ethereum Killer&#8217; Hyperliquid Explodes For 274% 7-Day Gain, Could Create &#8216;More Millionaires Than Microsoft At This Rate,&#8217; Trader Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$ETH

$SOL

$SUI

$TIA

Hyperliquid, The 'Coolest New Crypto Product,' Up 500% In 2 Weeks: 'Imagine Ethereum, Solana, Binance Had A Baby,' Lauds Trader

On Thursday, the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use adopted a positive opinion for an update for Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic&nbsp;(once-weekly subcutaneous semaglutide) label to reflect data from the FLOW kidney outcomes trial.
The FLOW trial <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915077" rel="noreferrer noopener">assessed</a> the risk reduction from Ozempic&nbsp;therapy in chronic kidney disease-related events.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42291660/defiance-etfs-introduces-leveraged-etf-to-capture-novo-nordisk-momentum-riding-high-on-weight-loss-medications" rel="noreferrer noopener">Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum</a>
In the FLOW trial, semaglutide 1.0 mg demonstrated a statistically significant and superior 24% risk reduction in kidney disease progression, cardiovascular disease, and kidney death compared to placebo.
The combined primary endpoint included five components measuring the progression of CKD and the risk of kidney <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37478859/novo-nordisk-says-famed-diabetes-medicine-ozempic-reduces-risk-of-kidney-disease-progression-data" rel="noreferrer noopener">and cardiovascular mortality</a>.&nbsp;
In addition, the secondary endpoints in the trial showed that the risk of major cardiovascular events was reduced by 18%, and the risk of all-cause mortality <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/39008722/novo-nordisk-releases-data-showing-ozempic-for-diabetes-slows-kidney-disease-progression" rel="noreferrer noopener">was reduced by 20%</a>.
Novo Nordisk has also filed for a label expansion in the US, and a decision is expected in the first half of 2025.
Last week, GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>), a prescription savings platform in the U.S., released its latest Weight Loss Medications Tracker, revealing a sharp increase in the use of popular weight loss drugs like Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro and Zepbound as well as Novo Nordisk&#8217;s <a href="https://www.benzinga.com/pressreleases/24/12/b42339270/goodrx-reveals-americans-overspent-on-weight-loss-medications-by-200-million-this-year-fills-still" target="_blank" rel="noreferrer noopener">Ozempic and Wegovy</a>.
Despite limited insurance coverage and high out-of-pocket costs, demand for these <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42349122/how-much-did-americans-overspend-on-weight-loss-medications-in-2024-goodrx-reveals" rel="noreferrer noopener">medications is soaring</a>.
Price Action: NVO stock is down 1.8% at $109.68 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42465157/gamblingcom-acquires-odds-holdings-in-160-million-deal-to-expand-online-gambling-reach" target="_blank" rel="noreferrer noopener">Gambling.com Rolls The Dice On OddsJam&#8217;s Parent; $80M Upfront Consideration For Instant Revenue Boost</a></li>
</ul>

Biotech

Eurozone

GDRX

Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel

U.S. stocks traded lower midway through trading, with the Dow Jones index falling by 0.2% on Thursday.
The Dow traded down 0.18% to 44,067.70 while the NASDAQ fell 0.33% to 19,969.33. The S&amp;P 500 also fell, dropping, 0.24% to 6,069.33.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-them">Jim Cramer Says &#8216;Keep Owning&#8217; This Energy Stock, Abbott Laboratories &#8216;Legal Stuff&#8217; Is Behind Them</a>
Leading and Lagging Sectors Real estate shares jumped by 0.7% on Thursday.
In trading on Thursday, energy shares fell by 0.6%.
Top Headline
Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) shares fell around 13% on Thursday following the company's release of a revenue forecast that fell short of expectations.
The company said it expects first-quarter revenue to be in the range of $5.63 billion to $5.68 billion versus estimates of $5.73 billion. The company anticipates first-quarter adjusted earnings of $4.95 to $5 per share versus estimates of $4.95 per share.
The company reported revenue of $5.61 billion, surpassing the consensus estimate of $5.54 billion. Adjusted earnings per share were $4.81, exceeding analyst predictions of $4.66 per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Liquidity Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDT#NASDAQ">LQDT</a>) shares shot up 26% to $32.51 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Shares of Trevi Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) got a boost, surging 60% to $3.9880 after the company announced positive outcomes for the treatment of patients from its chronic cough Phase 2b CORAL trial.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) shares were also up, gaining 17% to $3.9300 after the company inked a definitive agreement to sell its Geomagic software portfolio to Hexagon's Manufacturing Intelligence Division for $123 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Sacks Parente Golf, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPGC#NASDAQ">SPGC</a>) shares dropped 80% to $0.2950 after the company priced an upsized $8.4 million underwritten public offering of 7 million common units at $1.20 per unit.</li>
<li>Shares of Keros Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) were down 74% to $18.00 after the company announced it halted treatment in the 3.0 mg/kg and 4.5 mg/kg arms of its ongoing TROPOS trial due to safety concerns..</li>
<li>The Lovesac Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) was down, falling 25% to $28.39 after the company reported mixed third-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded down 1.6% to $69.17 while gold traded down 1.9% at $2,705.80.
Silver traded down 3.9% to $31.67 on Thursday, while copper fell 0.7% to $4.2330.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.09%, Germany's DAX rose 0.15% and France's CAC 40 gained 0.07%. Spain's IBEX 35 Index slipped 0.06%, while London's FTSE 100 rose 0.12%.
Asia Pacific Markets
Asian markets closed mostly higher on Thursday, with Japan's Nikkei 225 gaining 1.21%, Hong Kong's Hang Seng Index gaining 1.20%, China's Shanghai Composite Index gaining 0.85% and India's BSE Sensex falling 0.29%.
Economics
<ul>
<li>U.S. initial jobless claims increased by 17,000 from the previous week to a reading of 242,000 during the first week of December, compared to market estimates of 220,000.</li>
<li>Core producer prices increased by 0.2% month-over-month in November compared to a 0.3% increase in the previous month and in-line with market expectations.</li>
<li>U.S. natural-gas stocks fell 190 billion cubic feet to 3.747 trillion cubic feet in the week ended Dec. 6, compared to market estimates of a 170 billion cubic feet decline.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/24/12/42460506/wall-streets-most-accurate-analysts-weigh-in-on-3-risk-off-care-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Risk Off Care Stocks With Over 5% Dividend Yields</a></li>
</ul>

Commodities

Intraday Update

Markets

ADBE

KROS

LOVE

LQDT

SPGC

TRVI

Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook

Barrington Research analyst Vincent Colicchio maintains Climb Global Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>) with a Outperform and maintains $136 price target.

CLMB

Barrington Research Maintains Outperform on Climb Global Solutions, Maintains $136 Price Target

On Thursday, Pfizer Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Alliance Foundation Trials, LLC (AFT) announced results from the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42459402/pfizers-ibrance-in-combination-with-standard-of-care-therapies-extends-median-progression-free-sur" rel="noreferrer noopener">Phase 3 PATINA trial</a>.
The trial demonstrated that the addition of IBRANCE&nbsp;(palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42421011/arvinas-pfizer-partner-cancer-cancer-drug-shows-63-clinical-benefit-rate-in-combo-therapy-trial-in-breast-cancer-patients" rel="noreferrer noopener">Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients</a>
In the study, median PFS was 44.3 months for patients treated with IBRANCE in combination with anti-HER2 therapy (trastuzumab or trastuzumab plus pertuzumab) and endocrine therapy and 29.1 months for patients treated with anti-HER2 therapy and endocrine therapy alone.
This represents an extension in median PFS of over 15 months.
Overall survival, a secondary endpoint, was not yet mature at the time of the analysis.
The safety and tolerability of IBRANCE in the PATINA study were consistent with its known safety profile in HR+, human epidermal growth factor receptor 2-negative (HER2-) MBC, and no new safety signals were identified.
The most common adverse events observed with IBRANCE were hematologic toxicities, such as neutropenia and leukopenia.
Non-hematologic adverse events included fatigue, stomatitis, and diarrhea, which were generally mild to moderate in severity.
Since its initial regulatory approval in 2015, IBRANCE remains a standard-of-care first-line treatment for HR+, HER2- MBC and has been approved in more than 108 countries.
In 2023, Ibrance generated sales of $4.75 billion.
Price Action: PFE stock is up 0.24% at $25.29 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42462469/telehealth-firm-ro-partners-with-eli-lilly-to-boost-access-to-obesity-drug-zepbound" target="_blank" rel="noreferrer noopener">Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound</a></li>
</ul>
Photo via Shutterstock

Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$320.00</td>
<td>$38.1K</td>
<td>89</td>
<td align="right">557</td>
</tr>
<tr>
<td>BE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$25.00</td>
<td>$60.6K</td>
<td>2.6K</td>
<td align="right">554</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$130.00</td>
<td>$143.4K</td>
<td>3.7K</td>
<td align="right">504</td>
</tr>
<tr>
<td>LMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$500.00</td>
<td>$114.6K</td>
<td>840</td>
<td align="right">427</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$40.00</td>
<td>$41.5K</td>
<td>1.1K</td>
<td align="right">275</td>
</tr>
<tr>
<td>ALK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$65.00</td>
<td>$45.2K</td>
<td>39</td>
<td align="right">249</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For GEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), we notice a put option sweep that happens to be bearish, expiring in 71 day(s) on February 21, 2025. This event was a transfer of 21 contract(s) at a $320.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $38.1K, with a price of $1820.0 per contract. There were 89 open contracts at this strike prior to today, and today 557 contract(s) were bought and sold. 
• For BE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>), we notice a put option sweep that happens to be bearish, expiring in 8 day(s) on December 20, 2024. This event was a transfer of 551 contract(s) at a $25.00 strike. This particular put needed to be split into 50 different trades to become filled. The total cost received by the writing party (or parties) was $60.6K, with a price of $110.0 per contract. There were 2612 open contracts at this strike prior to today, and today 554 contract(s) were bought and sold. 
• Regarding VRT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>), we observe a call option sweep with neutral sentiment. It expires in 36 day(s) on January 17, 2025. Parties traded 239 contract(s) at a $130.00 strike. This particular call needed to be split into 26 different trades to become filled. The total cost received by the writing party (or parties) was $143.4K, with a price of $600.0 per contract. There were 3723 open contracts at this strike prior to today, and today 504 contract(s) were bought and sold. 
• For LMT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), we notice a put option sweep that happens to be bearish, expiring in 8 day(s) on December 20, 2024. This event was a transfer of 157 contract(s) at a $500.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $114.6K, with a price of $730.0 per contract. There were 840 open contracts at this strike prior to today, and today 427 contract(s) were bought and sold. 
• For RKLB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>), we notice a call option trade that happens to be neutral, expiring in 736 day(s) on December 18, 2026. This event was a transfer of 50 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $41.5K, with a price of $830.0 per contract. There were 1157 open contracts at this strike prior to today, and today 275 contract(s) were bought and sold. 
• Regarding ALK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>), we observe a put option sweep with bullish sentiment. It expires in 36 day(s) on January 17, 2025. Parties traded 174 contract(s) at a $65.00 strike. This particular put needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $45.2K, with a price of $260.0 per contract. There were 39 open contracts at this strike prior to today, and today 249 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

RKLB

6 Industrials Stocks Whale Activity In Today's Session

Bernstein analyst Mark Moerdler maintains Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) with a Outperform and lowers the price target from $644 to $587.

Bernstein Maintains Outperform on Adobe, Lowers Price Target to $587

The Benzinga Future of Digital Assets conference highlighted a critical discussion on digital asset portfolio risk management and return strategies. Industry experts shared insights on how Bitcoin ETFs and the emergence of related financial instruments reshape institutional participation.
<h4 class="wp-block-heading">ETFs as a Gateway for Institutional Access</h4>
During the panel, speakers emphasized the role of Bitcoin ETFs in streamlining institutional access. John Divine of Blockfills explained how ETFs simplify the process, enabling hedge funds and other market participants to engage with digital assets without building extensive crypto-native infrastructure. &#8220;ETFs are creating a path for traditional players to enter the market seamlessly,&#8221; he said.
Adam Guren of Hunting Hill Global Capital further highlighted how ETFs cater to institutional investors&#8217; operational preferences. The cash-settled structure of U.S. ETFs addresses key compliance and risk concerns, Guren explained, adding that their accessibility could drive more significant flows from institutional players.
<h4 class="wp-block-heading">Advanced Tools for Risk Management</h4>
With the advent of Bitcoin ETF options, new strategies for mitigating risk have emerged. Divine detailed how zero-cost collars, where investors sell call options to finance the purchase of protective put options, are gaining traction. &#8220;This strategy allows participants to cap downside risk while maintaining some exposure to potential upside,&#8221; he said.
Anthony Rousseau of TradeStation echoed these sentiments, discussing the broader implications of options trading. &#8220;Options create deeper liquidity and allow participants to express strategies more flexibly,&#8221; Rousseau said. He stressed the importance of understanding leverage, noting its dual-edged potential to amplify gains and losses.
<h4 class="wp-block-heading">Expanding Market Liquidity </h4>
The panel also explored how ETFs are fostering liquidity in digital asset markets. According to Divine, the basis trade—a common strategy where investors buy spot Bitcoin and sell futures contracts—has become increasingly attractive. &#8220;With annualized spreads of up to 16%, this approach draws interest from sophisticated players,&#8221; he said.
Scott Acheychek of REX Financial pointed out that ETF-linked liquidity mechanisms also transform traditional markets. &#8220;Covered call strategies and other structured products are extending the utility of digital assets beyond their native environments,&#8221; he explained.
<h4 class="wp-block-heading">Institutional Engagement and Future Outlook</h4>
The speakers unanimously agreed that Bitcoin ETFs accelerate institutional adoption by reducing operational barriers and providing familiar risk management tools. However, they cautioned against over exuberance. &#8220;While ETFs are opening doors, the market must remain vigilant about managing leverage and speculative excess,&#8221; Rousseau advised.
Looking ahead, Guren expressed optimism about the ongoing convergence of traditional and digital markets. &#8220;As these tools mature, we'll see greater alignment between onshore and offshore trading environments,&#8221; he said. This evolution, he noted, could lead to a more integrated and efficient global marketplace for digital assets.
Bitcoin ETFs are poised to play a pivotal role in institutional strategies by bridging the gap between traditional finance and cryptocurrency. As new financial instruments emerge, they promise to redefine how investors manage risk and optimize returns in an evolving market.

Events

Exclusives

Interview

ETFs

How Bitcoin ETFs Are Changing The Way Institutions Manage Risk According To Experts

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Consumer Discretionary sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$430.00</td>
<td>$46.1K</td>
<td>14.9K</td>
<td>83.9K</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$230.00</td>
<td>$46.3K</td>
<td>17.7K</td>
<td>26.3K</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$90.00</td>
<td>$38.7K</td>
<td>15.8K</td>
<td>5.5K</td>
</tr>
<tr>
<td>PVH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$105.00</td>
<td>$306.0K</td>
<td>557</td>
<td>600</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$20.00</td>
<td>$32.6K</td>
<td>8.6K</td>
<td>522</td>
</tr>
<tr>
<td>SFIX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.50</td>
<td>$25.7K</td>
<td>270</td>
<td>401</td>
</tr>
<tr>
<td>CMG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$31.8K</td>
<td>7.3K</td>
<td>142</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$35.00</td>
<td>$47.6K</td>
<td>2.9K</td>
<td>105</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$300.00</td>
<td>$52.7K</td>
<td>18</td>
<td>44</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on December 13, 2024. Parties traded 156 contract(s) at a $430.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $46.1K, with a price of $295.0 per contract. There were 14908 open contracts at this strike prior to today, and today 83941 contract(s) were bought and sold. 
• Regarding AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on December 13, 2024. Parties traded 286 contract(s) at a $230.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $46.3K, with a price of $162.0 per contract. There were 17780 open contracts at this strike prior to today, and today 26357 contract(s) were bought and sold. 
• For BABA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), we notice a call option trade that happens to be bullish, expiring in 8 day(s) on December 20, 2024. This event was a transfer of 244 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $38.7K, with a price of $159.0 per contract. There were 15825 open contracts at this strike prior to today, and today 5590 contract(s) were bought and sold. 
• Regarding PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>), we observe a put option trade with bullish sentiment. It expires in 99 day(s) on March 21, 2025. Parties traded 600 contract(s) at a $105.00 strike. The total cost received by the writing party (or parties) was $306.0K, with a price of $510.0 per contract. There were 557 open contracts at this strike prior to today, and today 600 contract(s) were bought and sold. 
• Regarding RIVN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), we observe a call option trade with bearish sentiment. It expires in 372 day(s) on December 19, 2025. Parties traded 125 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $32.6K, with a price of $261.0 per contract. There were 8659 open contracts at this strike prior to today, and today 522 contract(s) were bought and sold. 
• Regarding SFIX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>), we observe a call option trade with bullish sentiment. It expires in 400 day(s) on January 16, 2026. Parties traded 191 contract(s) at a $5.50 strike. The total cost received by the writing party (or parties) was $25.7K, with a price of $135.0 per contract. There were 270 open contracts at this strike prior to today, and today 401 contract(s) were bought and sold. 
• For CMG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), we notice a call option trade that happens to be neutral, expiring in 190 day(s) on June 20, 2025. This event was a transfer of 60 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $31.8K, with a price of $530.0 per contract. There were 7356 open contracts at this strike prior to today, and today 142 contract(s) were bought and sold. 
• For JD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), we notice a call option trade that happens to be bullish, expiring in 71 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $47.6K, with a price of $476.0 per contract. There were 2934 open contracts at this strike prior to today, and today 105 contract(s) were bought and sold. 
• For CVNA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), we notice a put option trade that happens to be bearish, expiring in 15 day(s) on December 27, 2024. This event was a transfer of 10 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $52.7K, with a price of $5276.0 per contract. There were 18 open contracts at this strike prior to today, and today 44 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMZN

BABA

CVNA

SFIX

9 Consumer Discretionary Stocks With Whale Alerts In Today's Session

Live On CNBC, Jim Lebenthal Announces Bought More UnitedHealth Group

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Information Technology sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$140.00</td>
<td>$38.6K</td>
<td>112.3K</td>
<td>35.5K</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$20.00</td>
<td>$29.8K</td>
<td>27.1K</td>
<td>29.5K</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$190.00</td>
<td>$85.3K</td>
<td>10.4K</td>
<td>7.2K</td>
</tr>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$450.00</td>
<td>$61.3K</td>
<td>33.9K</td>
<td>5.3K</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$129.00</td>
<td>$29.4K</td>
<td>4.0K</td>
<td>5.0K</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$400.00</td>
<td>$42.9K</td>
<td>9.0K</td>
<td>4.4K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$260.00</td>
<td>$237.7K</td>
<td>8.1K</td>
<td>4.0K</td>
</tr>
<tr>
<td>IONQ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$31.00</td>
<td>$57.5K</td>
<td>574</td>
<td>1.4K</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.00</td>
<td>$27.9K</td>
<td>6.0K</td>
<td>1.3K</td>
</tr>
<tr>
<td>APP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$400.00</td>
<td>$1.7 million</td>
<td>1.9K</td>
<td>950</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding NVDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), we observe a call option sweep with bearish sentiment. It expires in 8 day(s) on December 20, 2024. Parties traded 210 contract(s) at a $140.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $38.6K, with a price of $184.0 per contract. There were 112311 open contracts at this strike prior to today, and today 35549 contract(s) were bought and sold. 
• For RIOT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>), we notice a call option sweep that happens to be bearish, expiring in 190 day(s) on June 20, 2025. This event was a transfer of 116 contract(s) at a $20.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $29.8K, with a price of $259.0 per contract. There were 27100 open contracts at this strike prior to today, and today 29579 contract(s) were bought and sold. 
• For AVGO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), we notice a call option sweep that happens to be bearish, expiring in 1 day(s) on December 13, 2024. This event was a transfer of 316 contract(s) at a $190.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $85.3K, with a price of $270.0 per contract. There were 10408 open contracts at this strike prior to today, and today 7243 contract(s) were bought and sold. 
• For MSFT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), we notice a call option sweep that happens to be bullish, expiring in 8 day(s) on December 20, 2024. This event was a transfer of 80 contract(s) at a $450.00 strike. This particular call needed to be split into 29 different trades to become filled. The total cost received by the writing party (or parties) was $61.3K, with a price of $767.0 per contract. There were 33973 open contracts at this strike prior to today, and today 5331 contract(s) were bought and sold. 
• Regarding AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), we observe a call option trade with bearish sentiment. It expires in 1 day(s) on December 13, 2024. Parties traded 200 contract(s) at a $129.00 strike. The total cost received by the writing party (or parties) was $29.4K, with a price of $147.0 per contract. There were 4062 open contracts at this strike prior to today, and today 5078 contract(s) were bought and sold. 
• For MSTR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), we notice a call option trade that happens to be bearish, expiring in 1 day(s) on December 13, 2024. This event was a transfer of 44 contract(s) at a $400.00 strike. The total cost received by the writing party (or parties) was $42.9K, with a price of $975.0 per contract. There were 9072 open contracts at this strike prior to today, and today 4439 contract(s) were bought and sold. 
• Regarding AAPL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), we observe a call option sweep with bullish sentiment. It expires in 71 day(s) on February 21, 2025. Parties traded 450 contract(s) at a $260.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $237.7K, with a price of $528.0 per contract. There were 8117 open contracts at this strike prior to today, and today 4066 contract(s) were bought and sold. 
• Regarding IONQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on December 13, 2024. Parties traded 500 contract(s) at a $31.00 strike. This particular put needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $57.5K, with a price of $115.0 per contract. There were 574 open contracts at this strike prior to today, and today 1411 contract(s) were bought and sold. 
• Regarding RGTI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>), we observe a call option sweep with bearish sentiment. It expires in 36 day(s) on January 17, 2025. Parties traded 499 contract(s) at a $13.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.9K, with a price of $56.0 per contract. There were 6081 open contracts at this strike prior to today, and today 1391 contract(s) were bought and sold. 
• Regarding APP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), we observe a call option trade with bearish sentiment. It expires in 99 day(s) on March 21, 2025. Parties traded 600 contract(s) at a $400.00 strike. The total cost received by the writing party (or parties) was $1.7 million, with a price of $2920.0 per contract. There were 1985 open contracts at this strike prior to today, and today 950 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

AVGO

IONQ

MSFT

MSTR

NVDA

RGTI

RIOT

10 Information Technology Stocks Whale Activity In Today's Session

WIIM

GATO

PAAS

Shares of silver companies are trading lower amid a drop in the price of the commodity.

Comcast Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) plans to <a href="https://www.benzinga.com/24/11/41999904/disney-ceo-bob-iger-slams-the-brakes-on-new-ma-amid-comcasts-cable-spinoff-we-dont-need-more-assets-to-compete-in-todays-disruptive-media-landscape">spin off its cable networks into a new company</a>.
The stock declined by 9% since Monday after management guided to "a marginal competitively driven increase in Broadband subscriber losses" and the shares are currently "oversold," according to Seaport Research Partners.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58f614b60bd9910001a77adf/david-joyce">Analyst David Joyce</a> upgraded the rating for Comcast from Neutral to Buy, while maintaining the price target at $46.
The Comcast Thesis: Comcast Cable&#8217;s CEO indicated that broadband competition had intensified and guided to a net loss of 100,000 subscribers in the fourth quarter of 2024, Joyce said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
This is only 33,000 lower than the previous estimate, on Comcast's base of 32 million subscribers, and the stock reactions seems "overdone," he added.
"Concurrently, Comcast announced a broad-reaching distribution renewal with Warner Bros. Discovery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) for linear and Max properties domestically and with Comcast&#8217;s Sky in Europe — this should be construed positively for both CMCSA and WBD," the analyst wrote.
This makes Comcast "appear constructive on supporting the broader linear industry ahead of its Cable Networks spinoff later in 2025," he added.
CMCSA Price Action: Shares of Comcast had risen by 1.04% to $40.12 at the time of publication on Thursday.
Read More: • <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42395322/warner-bros-discovery-stock-soars-after-multi-year-deal-with-comcast-comcast-shares-slide-on-subscriber-loss-estimates">Warner Bros Discovery Stock Soars After Multi-Year Deal with Comcast; Comcast Shares Slide On Subscriber Loss Estimates</a>

Long Ideas

Upgrades

CMCSA

Comcast Shares Tank 7% Since Monday: Market Reaction To Q4 Subscriber Loss Guidance Is 'Overdone,' Says Bullish Analyst

D. Boral Capital analyst Jason Kolbert maintains Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) with a Buy and maintains $21 price target.

D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target

D. Boral Capital analyst Jesse Sobelson initiated coverage of Rezolve AI (RZLV) with a Buy rating and $8 price target Rezolve is a U.K.-based artif...

Rezolve AI initiated with a Buy at D. Boral Capital

Rezolve Ai (RZLV) and Google (GOOGL) signed a strategic partnership to accelerate the transformation of retail and consumer commerce through advanc...

Rezolve AI, Google sign strategic partnership for AI-powered solutions

Rezolve AI (RZLV) has announced back-to-back strategic reseller partnerships with Microsoft (MSFT) and Google (GOOGL), two of the most prominent le...

Rezolve AI strengthens enters partnerships with Google, Microsoft

Both Microsoft ($MSFT) and Google ($GOOGL) are betting on a little-known software startup called Rezolve AI ($RZLV). Founded in 2024, Rezolve uses ...

Both Microsoft and Google Are Betting On Rezolve AI (NASDAQ:RZLV)

Rezolve Ai (RZLV) is announcing a new product designed with support from Tether to revolutionize retail payments. Rezolve Ai will integrate WDK by ...

Rezolve AI, Tether share vision to make crypto mainstream

Cantor Fitzgerald initiated coverage of Rezolve AI (RZLV) with an Overweight rating and $5 price target Published first on TheFly – the ultimate so...

Rezolve AI initiated with an Overweight at Cantor Fitzgerald

Rezolve AI (RZLV) has received a new Buy rating, initiated by Roth MKM analyst, Rohit Kulkarni. Rohit Kulkarni has given his Buy rating due to a co...

Rezolve AI: Buy Rating Driven by Strategic Positioning and Key Partnerships in E-commerce AI

Roth MKM analyst Rohit Kulkarni initiated coverage of Rezolve AI (RZLV) with a Buy rating and $4 price target Rezolve AI is an e-commerce artic ail...

Rezolve AI initiated with a Buy at Roth MKM

Rezolve AI gains as Roth MKM starts with Buy rating

Rezolve Ai (RZLV) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>), a global leader in retail artificial intelligence, today announced its active participation in initiatives that a...

Rezolve AI announces participation in initiatives expected to align with DOGE

GOOG

GOOGL

RZLV

Screenshot 2024-10-31 at 9.14.17 PM

Emerging Markets

Movers & Shakers

The Tech Driving Rezolve Ai&#39;s Mission To Transform Retail, And What Sets It Apart From The Pack

Screenshot 2024-10-10 at 5.27.06 PM

AI Specialist Rezolve Ai Forges Strategic Alliance And Co-Sell Support With Microsoft To Transform The Retail Industry

Screenshot 2024-10-07 at 5.55.01 PM

Rezolve AI Wants To Push The Boundaries Of Online Sales And Improving Consumer Experience

Screenshot 2024-09-17 at 5.36.23 PM

Rezolve Ai Inks Three Key Partnerships, Expanding The Customer Base For Its AI-Powered Platform For E-Commerce Businesses

Screenshot 2024-08-26 at 5.29.49 PM

E-commerce In The Age Of Artificial Intelligence

Screenshot 2024-08-16 at 7.35.33 PM

AACI

EBAY

Rezolve Debuts On Nasdaq And Looks To Level Up E-commerce With AI-Powered Sales Engine

The Tech Driving Rezolve Ai's Mission To Transform Retail, And What Sets It Apart From The Pack

Press Releases

Rezolve Ai to Present at Sidoti Virtual Investor Conference November 13-14, 2024

Rezolve Ai Announces Initiation of Equity Analyst Coverage by D. Boral Capital

Rezolve Ai to Participate in 13th Annual ROTH Technology Conference November 19-20, 2024

gkv informatik Selects Rezolve Ai's Brain Suite to Drive Productivity and Innovation in the Healthcare Sector

Rezolve Ai and Google Sign Strategic Partnership to Revolutionize Retail and Consumer Commerce with Exclusive AI-Powered Solutions

Rezolve Ai Strengthens Position in $7.6 Billion Conversational Commerce Market (Expected to Reach $34.41 Billion by 2034) following Strategic Partnerships with Microsoft and Google

Tether and Rezolve Ai Share Vision to Make Crypto Mainstream, Eliminate Merchant Fees, and Redefine Retail Payments

Recent Bitcoin Gains and SEC Chairman Nominee Anticipated to Lay Strong Foundation for Rezolve Ai's Vision to Make Crypto Mainstream

Rezolve Ai Aligns with Planned Department of Government Efficiency (DOGE) Initiatives to Transform Retail with AI-Driven Solutions and Workforce Optimization

Roth MKM

Cantor Fitzgerald

Rezolve AI shares are trading higher after the company announced it will participate in initiatives and provide solutions with the Department of Government Efficiency.

Comments

Rezolve AI

Noticias

Últimas noticias sobre Rezolve AI (NASDAQ:RZLV) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL